Rebooting immunity: can vaccines shield childhood cancer survivors from preventable diseases?

NCT ID NCT00505063

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates how well routine childhood vaccines work in children who have recently finished chemotherapy for cancer. The goal is to see if revaccination can restore protective immunity against diseases like measles, mumps, and whooping cough. Participants receive a series of standard vaccines over several months, and their antibody levels are measured to gauge protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a series of routine childhood vaccines (Prevnar 13, Menactra II, MMR, varicella, HPV, Hib, Pediarix, hepatitis B)
What this could lead to
If successful, this could establish a standard revaccination schedule to protect childhood cancer survivors from preventable diseases like measles, mumps, and whooping cough.
What could go wrong
This is a relatively small, single-center trial, and immune responses may vary widely in children whose immune systems are still recovering from chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.